T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

NCT03022435

Influenza

COMPLETED PHASE4

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013

NCT03023176

Influenza

COMPLETED PHASE4

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010

NCT03022396

Influenza

COMPLETED PHASE4

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

NCT01987349

Influenza

COMPLETED PHASE4

B-cell Immunity to Influenza (SLVP017)- Year 5, 2013

NCT03020537

Influenza

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators plan to study the response to influenza vaccines much more broadly and deeply across different age groups and with different vaccine formulations and to probe the influence of genetics on these responses using monozygotic and dizygotic twins. On an investigational basis, investigators plan to compare various immunological responses, identify age-specific biomarkers or clusters of markers, quantify the frequency of influenza-specific T-cells pre- and post-vaccination, and determine the effective breadth of T-cell repertoire to an influenza vaccine within an individual as a function of age and to what degree this is genetically determined.

Twin Groups B-E will receive a single administration of the 2011-2012 formulation of seasonal trivalent inactivated influenza vaccine (TIV). Group F, elderly monozygotic twin participants, will be randomly assigned to receive a single dose of inactivated vaccine, either the usual dose or the High-Dose TIV. Blood samples to conduct the assays described will be taken at pre-immunization, Days 7-10 and 28 post-immunization. The number of individual participants, not the number of twin pairs is being reported in all the modules.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group B: 18-30 yo identical twins (TIV)

Individual twins to receive Fluzone® standard TIV

Group Type OTHER

TIV

Intervention Type BIOLOGICAL

Influenza Virus Vaccine Suspension for Intramuscular Injection

Group C: 18-30 yo fraternal twins (TIV)

Individual twins to receive Fluzone® standard TIV

Group Type OTHER

TIV

Intervention Type BIOLOGICAL

Influenza Virus Vaccine Suspension for Intramuscular Injection

Group D: 40-64 yo identical twins (TIV)

Individual twins to receive Fluzone® standard TIV

Group Type OTHER

TIV

Intervention Type BIOLOGICAL

Influenza Virus Vaccine Suspension for Intramuscular Injection

Group E: 40-64 yo fraternal twins (TIV)

Individual twins to receive Fluzone® standard TIV

Group Type OTHER

TIV

Intervention Type BIOLOGICAL

Influenza Virus Vaccine Suspension for Intramuscular Injection

Group F: 65-100 yo identical twins (TIV)

Individual twins to receive Fluzone® standard TIV

Group Type OTHER

TIV

Intervention Type BIOLOGICAL

Influenza Virus Vaccine Suspension for Intramuscular Injection

Group F: 65-100 yo identical twins (High-Dose TIV)

Individual twins to receive High-Dose Fluzone® TIV

Group Type OTHER

High-Dose TIV

Intervention Type BIOLOGICAL

High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TIV

Influenza Virus Vaccine Suspension for Intramuscular Injection

Intervention Type BIOLOGICAL

High-Dose TIV

High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fluzone® TIV High-Dose Fluzone® TIV

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Otherwise healthy, ambulatory adults, ages 18-30 years (identical or fraternal twin pairs), 40-64 years (identical or fraternal twin pairs) or 65-100 years (identical twin pairs).
2. Willing to complete the informed consent process.
3. Availability for follow-up for the planned duration of the study at least 28 days after immunization.
4. Acceptable medical history and vital signs.

Exclusion Criteria

1. Prior off-study vaccination with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV) in Fall 2011
2. Allergy to egg or egg products, or to vaccine components, including thimerosal (if TIV multidose vials used)
3. Allergy to latex (for Group F only - may be assigned to Fluzone High-Dose). Review with investigator.
4. Life-threatening reactions to previous influenza vaccinations
5. Active systemic or serious concurrent illness, including febrile illness on the day of vaccination
6. History of immunodeficiency (including HIV infection)
7. Known or suspected impairment of immunologic function, including, but not limited to, clinically significant liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease or any other chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
8. Blood pressure \>150 systolic or \> 95 diastolic at Visit 1
9. Hospitalization in the past year for congestive heart failure or emphysema.
10. Chronic Hepatitis B or C
11. Recent or current use of immunosuppressive medication, including glucocorticoids (corticosteroid nasal sprays, topical steroids and inhaled steroids are permissible). Use of oral steroids (\<20mg prednisone-equivalent/day) may be acceptable after review by the investigator.
12. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors such as breast cancer or prostate cancer with recurrence in the past year, and any hematologic cancer such as leukemia).
13. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
14. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year
15. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin (except aspirin up to 325 mg.day), Plavix, or Aggrenox must be reviewed by investigator to determine if this would affect the volunteer's safety.
16. Receipt of blood or blood products within the past 6 months
17. Medical or psychiatric condition or occupational responsibilities that preclude participant compliance with the protocol
18. Inactivated vaccine 14 days prior to vaccination
19. Live, attenuated vaccine within 60 days of vaccination
20. History of Guillain-Barre Syndrome
21. Pregnant or lactating woman
22. Use of investigational agents within 30 days prior to enrollment
23. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment
24. Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes